Dear compound submitter,
Thank you for considering working with the E4C consortium to help identify new treatments against SARS-Cov-2.
We will make careful use of your compound structures. The information you provide will be used as input into our High Performance Computing resources for virtual screening against priority target protein structures. Upon completion of the analyses, we will flag the compounds which our teams identify as being interesting for further development and then inform you of the process to further profile the compounds in our in-vitro target based assays.
Following mutual agreement to the terms of the in-vitro screening agreement (currently being prepared), you will then need to provide us with chemical material in the agreed quantity and we will provide screening slots for those selected compounds.
Screening results on the compounds will be published, within 30 days of data production, on a public portal such as ChEMBL.
If you think this is acceptable to you, please send us your structures.
We look forward to working with you!